123 related articles for article (PubMed ID: 24490776)
21. MicroRNAs in malignant melanoma.
Völler D; Ott C; Bosserhoff A
Clin Biochem; 2013 Jul; 46(10-11):909-17. PubMed ID: 23360785
[TBL] [Abstract][Full Text] [Related]
22. [Molecular classification and markers of malignant melanoma].
Tímár J; Hársing J; Somlai B
Magy Onkol; 2013 Jun; 57(2):73-8. PubMed ID: 23795351
[TBL] [Abstract][Full Text] [Related]
23. Tg(Grm1) transgenic mice: a murine model that mimics spontaneous uveal melanoma in humans?
Schiffner S; Braunger BM; de Jel MM; Coupland SE; Tamm ER; Bosserhoff AK
Exp Eye Res; 2014 Oct; 127():59-68. PubMed ID: 25051141
[TBL] [Abstract][Full Text] [Related]
24. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
[TBL] [Abstract][Full Text] [Related]
25. Signatures of microRNAs and selected microRNA target genes in human melanoma.
Philippidou D; Schmitt M; Moser D; Margue C; Nazarov PV; Muller A; Vallar L; Nashan D; Behrmann I; Kreis S
Cancer Res; 2010 May; 70(10):4163-73. PubMed ID: 20442294
[TBL] [Abstract][Full Text] [Related]
26. Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of "melanotic schwannoma".
Torres-Mora J; Dry S; Li X; Binder S; Amin M; Folpe AL
Am J Surg Pathol; 2014 Jan; 38(1):94-105. PubMed ID: 24145644
[TBL] [Abstract][Full Text] [Related]
27. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.
Gebhardt C; Lichtenberger R; Utikal J
J Dtsch Dermatol Ges; 2016 Feb; 14(2):158-64. PubMed ID: 26819111
[TBL] [Abstract][Full Text] [Related]
28. A potential predictive marker for response to interferon in malignant melanoma.
Wild PJ; Meyer S; Landthaler M; Hofstaedter F; Bosserhoff AK
J Dtsch Dermatol Ges; 2007 Jun; 5(6):456-9. PubMed ID: 17537037
[TBL] [Abstract][Full Text] [Related]
29. Strategy for SRM-based verification of biomarker candidates discovered by iTRAQ method in limited breast cancer tissue samples.
Muraoka S; Kume H; Watanabe S; Adachi J; Kuwano M; Sato M; Kawasaki N; Kodera Y; Ishitobi M; Inaji H; Miyamoto Y; Kato K; Tomonaga T
J Proteome Res; 2012 Aug; 11(8):4201-10. PubMed ID: 22716024
[TBL] [Abstract][Full Text] [Related]
30. Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.
Crende O; Sabatino M; Valcárcel M; Carrascal T; Riestra P; López-Guerrero JA; Nagore E; Mandruzzato S; Wang E; Marincola FM; Vidal-Vanaclocha F
Am J Pathol; 2013 Jul; 183(1):69-82. PubMed ID: 23707237
[TBL] [Abstract][Full Text] [Related]
31. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
Harpio R; Einarsson R
Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of sex determining region Y-box 11 (SOX11) in cutaneous malignant melanoma.
Jian J; Guoying W; Jing Z
J Int Med Res; 2013 Aug; 41(4):1221-7. PubMed ID: 23867449
[TBL] [Abstract][Full Text] [Related]
33. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
34. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma.
Rossi M; Tuck J; Kim OJ; Panova I; Symanowski JT; Mahalingam M; Riker AI; Alani RM; Ryu B
Br J Dermatol; 2014 Aug; 171(2):403-8. PubMed ID: 24359286
[TBL] [Abstract][Full Text] [Related]
35. Quantitative proteomic analysis of microdissected breast cancer tissues: comparison of label-free and SILAC-based quantification with shotgun, directed, and targeted MS approaches.
Liu NQ; Dekker LJ; Stingl C; Güzel C; De Marchi T; Martens JW; Foekens JA; Luider TM; Umar A
J Proteome Res; 2013 Oct; 12(10):4627-41. PubMed ID: 23957277
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
37. Melanoma gene expression and clinical course.
Vourc'h-Jourdain M; Volteau C; Nguyen JM; Khammari A; Dreno B
Arch Dermatol Res; 2009 Oct; 301(9):673-9. PubMed ID: 19326132
[TBL] [Abstract][Full Text] [Related]
38. Improving SRM assay development: a global comparison between triple quadrupole, ion trap, and higher energy CID peptide fragmentation spectra.
de Graaf EL; Altelaar AF; van Breukelen B; Mohammed S; Heck AJ
J Proteome Res; 2011 Sep; 10(9):4334-41. PubMed ID: 21726076
[TBL] [Abstract][Full Text] [Related]
39. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
40. DMBT1 expression distinguishes anorectal from cutaneous melanoma.
Helmke BM; Renner M; Poustka A; Schirmacher P; Mollenhauer J; Kern MA
Histopathology; 2009 Jan; 54(2):233-40. PubMed ID: 19207948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
